GLP-1 Receptor Agonist

Semaglutide: Overview, Dosage, Side Effects & Research

The peptide that started the weight loss revolution — FDA-approved, clinically proven, and widely accessible.

Also known as: Ozempic, Wegovy, Rybelsus

14.9%
Weight Loss (24mg)
1961
Trial Participants
Phase 3
Not FDA Approved

What is Semaglutide?

Semaglutide mimics the natural GLP-1 hormone, which is released from the gut after eating. It activates GLP-1 receptors in the pancreas (stimulating insulin), brain (suppressing appetite), and stomach (slowing gastric emptying). The result is reduced caloric intake, improved blood sugar control, and significant weight loss.

Typical Dose
1.7-2.4 mg
Frequency
Once weekly (injectable); once daily (Rybelsus oral)
Half-Life
~7 days
Administration
Subcutaneous injection (abdomen, thigh, upper arm)
Approval Status
FDA approved for T2D (Ozempic, 2017), obesity (Wegovy, 2021), CV risk reduction (2023), oral T2D (Rybelsus, 2019)
Legal Status
FDA approved. Requires prescription. Widely available through physicians and telehealth.

Dosage Overview

LevelDose
Starting / Low0.25 mg
Typical / Maintenance1.7-2.4 mg
Maximum (studied)2.4 mg

For Wegovy: Start at 0.25mg weekly, titrate by 0.25mg every 4 weeks up to 2.4mg maintenance dose. For Ozempic: Max dose is 2mg. Oral Rybelsus dose is 3mg daily titrating to 14mg.

Full dosage guide with titration schedule →

Side Effects

Side EffectFrequency
Nauseacommon
Diarrheacommon
Vomitingcommon
Constipationcommon
Abdominal paincommon
Headachecommon
Full side effects guide with management tips →

Clinical Research

Phase 3 (STEP 1)
Weight reduction in adults with obesity

Semaglutide 2.4mg produced 14.9% mean weight loss vs 2.4% for placebo over 68 weeks.

Source: NEJM 2021; STEP 1 Trial
Phase 3 (SELECT)
Cardiovascular outcomes in overweight/obese patients

Semaglutide reduced major cardiovascular events (MACE) by 20% vs placebo in patients with established cardiovascular disease — a landmark finding leading to expanded use.

Source: NEJM 2023; SELECT Trial

Best Used For

Related Peptides

Exploring Retatrutide Access?

See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.

Not FDA approved. Access requires physician oversight.

Affiliate links — we may earn a commission at no cost to you.

Compare Providers →

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide but at different doses. Ozempic (max 2mg) is approved for type 2 diabetes. Wegovy (max 2.4mg) is approved for chronic weight management in obesity. Wegovy's higher dose produces greater weight loss.

Is compounded semaglutide available?

During the FDA-designated semaglutide shortage period (which affected much of 2022–2024), 503B compounding pharmacies were permitted to produce compounded semaglutide. Check current FDA shortage status, as availability changes.

How long does it take Semaglutide to work?

Most people notice appetite suppression within the first 1–2 weeks. Meaningful weight loss typically appears by weeks 4–8. Full effect at maintenance dose is seen by 12–20 weeks.

What happens when you stop Semaglutide?

Clinical studies show most patients regain a significant portion of lost weight (up to two-thirds) within one year of stopping semaglutide. This underscores that it treats obesity as a chronic condition requiring ongoing medication.

Where to Source Semaglutide

Sourcing guidance, supplier vetting criteria, and price benchmarks.

View Sourcing Guide →

Related Reading